Lilly’s $3.35B China Bet, Healthcare M&A’s Bottleneck, Biotech’s New Pipeline

Good morning, ! Healthcare dealmaking is getting more global—and more complicated. Lilly is making a $3.35B bet on Chinese biotech, China-linked drug licensing has reached $120B, and healthcare executives can’t agree on what’s actually holding M&A back: regulation, financing costs, or integration risk.

Plus, the FDA clears another once-weekly insulin, and we track the latest billion-dollar licensing deals shaping pharma’s next pipeline.

Know someone who would love this? Pass it along—they’ll thank you later! Here’s the link.

MICROSURVEY

Healthcare M&A Has Three Different Bottlenecks

Healthcare leaders agree that M&A faces friction over the next 12 months. They disagree sharply on where it will come from.

Among clinical and healthcare leadership, 50% identify regulatory uncertainty as the biggest constraint. Finance and investment executives see a different problem, with 50% pointing to financing costs. Operations and technology leaders are more divided, led by integration risk at 33%, followed by regulatory uncertainty at 27%.

The divergence matters. The same transaction can look attractive on valuation and still fail the internal test because the buyer is underwriting regulatory exposure, cost of capital, and post-close execution through different lenses. Notably, valuations never rank as the leading constraint for any group, topping out at 20%.

For dealmakers, the implication is that unlocking M&A may depend less on sellers resetting price expectations and more on buyers resolving their own functional risk concerns.

Bottom line: Healthcare M&A does not have one bottleneck. It has three, and the constraint depends on who is sitting at the table. (More)

HEADLINE OF THE WEEK

FDA Clears Lilly’s Once-Weekly Insulin : Diabetes Care Shifts From Daily to Weekly Dosing

So What? The September 24 approval of Lilly’s Onswik gives U.S. adults with type 2 diabetes another once-weekly basal insulin option, reinforcing a structural shift toward lower-burden chronic therapies that could improve adherence while intensifying competition across the enormous diabetes market.

The approval was supported by four Phase 3 QWINT trials involving more than 3,400 adults, where once-weekly Onswik delivered HbA1c reductions comparable to daily basal insulins; Lilly says the regimen can eliminate more than 300 injections per year versus once-daily dosing. (More)

DEAL OF THE WEEK

Lilly’s $3.35B China Bet

Eli Lilly and InnoCare Pharma signed a research collaboration and licensing agreement worth up to ~$3.35B, including up to $100M in upfront and near-term payments. The partnership covers up to five undisclosed drug targets, with another ~$3.25B tied to development and commercial milestones, plus tiered royalties.

The deal highlights global pharma’s growing appetite for China-sourced innovation. Rather than acquiring entire companies, licensing agreements give strategic buyers access to promising pipelines with less upfront capital and development risk—while giving biotech investors another potential route to liquidity and strategic exits.

Read more

REGIONAL FOCUS

China’s Biotech Pipeline Becomes Global Infrastructure

China’s biopharma ambitions are shifting from pipeline scale to original innovation. Beijing’s new five year plan targets at least 25% of global first in class drugs by 2030, alongside 50 domestic drugmakers generating more than $1.5B each in annual revenue and at least five global blockbusters.

Capital is already validating the direction. China linked innovative drug out licensing has reached $120B in total deal value this year. The chart shows how aggressively global pharma is competing for those assets. Pfizer’s 3SBio agreement carried a $1.35B upfront, while Novo Nordisk and AstraZeneca have committed upfront payments of $1.3B and $1.2B in major licensing transactions. Oncology remains the clear center of gravity.

The strategic implication is bigger than deal volume. China is becoming a pipeline origination market for Western pharma facing patent expirations and expensive internal R&D. If proposed U.S. rules preserve most pharmaceutical licensing activity with China, that integration could deepen further.

For investors and operators, China exposure is increasingly embedded in global drug development, whether through licensing, co development, or competitive pressure. Beijing’s next objective is to convert that dependence into durable economics and globally owned products. (More)

DEAL TRACKER

Nanexa → Novo Nordisk | Up to €1.165B
Novo Nordisk licensed Nanexa’s PharmaShell® technology for up to five obesity and diabetes programs, with €615M upfront and milestones, plus royalties. Read more

Earendil Labs → Genentech (Roche) | $1.5B+ potential
Genentech signed a bispecific discovery partnership with Earendil, including $55M upfront and more than $1.5B in potential consideration. Read more

Atavistik Bio → Roche | Up to $1.97B
Roche partnered with Atavistik around its drug-discovery platform, with $70M upfront and up to $1.9B in milestones. Read more

StatLab → Leica Biosystems (Danaher) | Undisclosed
Audax Private Equity and Linden Capital Partners sold StatLab, a pathology consumables and reagents provider, to Danaher’s Leica Biosystems. Read more

INTERESTING ARTICLES